Fideuram Intesa Sanpaolo Private Banking S.P.A. Acquires New Shares in Ascendis Pharma A/S $ASND

Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in Ascendis Pharma A/S (NASDAQ:ASND) in the 4th quarter, Holdings Channel.com reports. The institutional investor acquired 10,866 shares of the biotechnology company’s stock, valued at approximately $2,317,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Avoro Capital Advisors LLC raised its holdings in shares of Ascendis Pharma A/S by 2.6% in the third quarter. Avoro Capital Advisors LLC now owns 5,110,000 shares of the biotechnology company’s stock valued at $1,015,919,000 after acquiring an additional 130,000 shares in the last quarter. Capital International Investors raised its holdings in shares of Ascendis Pharma A/S by 0.4% in the third quarter. Capital International Investors now owns 3,060,616 shares of the biotechnology company’s stock valued at $608,481,000 after acquiring an additional 13,685 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Ascendis Pharma A/S by 95.9% in the third quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company’s stock valued at $357,645,000 after acquiring an additional 880,836 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Ascendis Pharma A/S by 29.3% in the fourth quarter. Principal Financial Group Inc. now owns 1,026,407 shares of the biotechnology company’s stock valued at $218,871,000 after acquiring an additional 232,730 shares in the last quarter. Finally, Perceptive Advisors LLC bought a new stake in shares of Ascendis Pharma A/S in the second quarter valued at about $166,367,000.

Insider Buying and Selling at Ascendis Pharma A/S

In other news, insider Flemming Steen Jensen sold 19,460 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $238.49, for a total transaction of $4,641,015.40. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 40.00% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on ASND shares. Oppenheimer lifted their target price on Ascendis Pharma A/S from $246.00 to $262.00 and gave the company an “outperform” rating in a research note on Thursday, February 12th. Citigroup started coverage on Ascendis Pharma A/S in a research note on Monday. They issued a “buy” rating and a $355.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ascendis Pharma A/S in a research note on Wednesday, January 21st. Jefferies Financial Group started coverage on Ascendis Pharma A/S in a research note on Monday, March 16th. They issued a “buy” rating and a $290.00 target price on the stock. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $255.00 target price on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $295.39.

Ascendis Pharma A/S Price Performance

ASND opened at $241.34 on Thursday. Ascendis Pharma A/S has a 1 year low of $153.49 and a 1 year high of $250.74. The firm has a market capitalization of $15.05 billion, a PE ratio of 27.84 and a beta of 0.41. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.00 and a quick ratio of 0.72. The business’s 50-day moving average is $232.15 and its two-hundred day moving average is $221.32.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.11. The business had revenue of $285.45 million for the quarter, compared to analysts’ expectations of $362.47 million. Research analysts anticipate that Ascendis Pharma A/S will post 12.19 earnings per share for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.